Cargando…

Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation

Cutaneous squamous cell carcinoma (cSCC) is the second-most common type of non-melanoma skin cancer and is linked to long-term exposure to ultraviolet (UV) radiation from the sun. Rocuronium bromide (RocBr) is an FDA-approved drug that targets p53-related protein kinase (PRPK) that inhibits the deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz, Victor H., Encinas-Basurto, David, Sun, Bo, Eedara, Basanth Babu, Roh, Eunmiri, Alarcon, Neftali Ortega, Curiel-Lewandrowski, Clara, Bode, Ann M., Mansour, Heidi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218466/
https://www.ncbi.nlm.nih.gov/pubmed/37240122
http://dx.doi.org/10.3390/ijms24108776
_version_ 1785048780256575488
author Ruiz, Victor H.
Encinas-Basurto, David
Sun, Bo
Eedara, Basanth Babu
Roh, Eunmiri
Alarcon, Neftali Ortega
Curiel-Lewandrowski, Clara
Bode, Ann M.
Mansour, Heidi M.
author_facet Ruiz, Victor H.
Encinas-Basurto, David
Sun, Bo
Eedara, Basanth Babu
Roh, Eunmiri
Alarcon, Neftali Ortega
Curiel-Lewandrowski, Clara
Bode, Ann M.
Mansour, Heidi M.
author_sort Ruiz, Victor H.
collection PubMed
description Cutaneous squamous cell carcinoma (cSCC) is the second-most common type of non-melanoma skin cancer and is linked to long-term exposure to ultraviolet (UV) radiation from the sun. Rocuronium bromide (RocBr) is an FDA-approved drug that targets p53-related protein kinase (PRPK) that inhibits the development of UV-induced cSCC. This study aimed to investigate the physicochemical properties and in vitro behavior of RocBr. Techniques such as thermal analysis, electron microscopy, spectroscopy and in vitro assays were used to characterize RocBr. A topical oil/water emulsion lotion formulation of RocBr was successfully developed and evaluated. The in vitro permeation behavior of RocBr from its lotion formulation was quantified with Strat-M(®) synthetic biomimetic membrane and EpiDerm™ 3D human skin tissue. Significant membrane retention of RocBr drug was evident and more retention was obtained with the lotion formulation compared with the solution. This is the first systematic and comprehensive study to report these findings.
format Online
Article
Text
id pubmed-10218466
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102184662023-05-27 Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation Ruiz, Victor H. Encinas-Basurto, David Sun, Bo Eedara, Basanth Babu Roh, Eunmiri Alarcon, Neftali Ortega Curiel-Lewandrowski, Clara Bode, Ann M. Mansour, Heidi M. Int J Mol Sci Article Cutaneous squamous cell carcinoma (cSCC) is the second-most common type of non-melanoma skin cancer and is linked to long-term exposure to ultraviolet (UV) radiation from the sun. Rocuronium bromide (RocBr) is an FDA-approved drug that targets p53-related protein kinase (PRPK) that inhibits the development of UV-induced cSCC. This study aimed to investigate the physicochemical properties and in vitro behavior of RocBr. Techniques such as thermal analysis, electron microscopy, spectroscopy and in vitro assays were used to characterize RocBr. A topical oil/water emulsion lotion formulation of RocBr was successfully developed and evaluated. The in vitro permeation behavior of RocBr from its lotion formulation was quantified with Strat-M(®) synthetic biomimetic membrane and EpiDerm™ 3D human skin tissue. Significant membrane retention of RocBr drug was evident and more retention was obtained with the lotion formulation compared with the solution. This is the first systematic and comprehensive study to report these findings. MDPI 2023-05-15 /pmc/articles/PMC10218466/ /pubmed/37240122 http://dx.doi.org/10.3390/ijms24108776 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ruiz, Victor H.
Encinas-Basurto, David
Sun, Bo
Eedara, Basanth Babu
Roh, Eunmiri
Alarcon, Neftali Ortega
Curiel-Lewandrowski, Clara
Bode, Ann M.
Mansour, Heidi M.
Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation
title Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation
title_full Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation
title_fullStr Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation
title_full_unstemmed Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation
title_short Innovative Rocuronium Bromide Topical Formulation for Targeted Skin Drug Delivery: Design, Comprehensive Characterization, In Vitro 2D/3D Human Cell Culture and Permeation
title_sort innovative rocuronium bromide topical formulation for targeted skin drug delivery: design, comprehensive characterization, in vitro 2d/3d human cell culture and permeation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218466/
https://www.ncbi.nlm.nih.gov/pubmed/37240122
http://dx.doi.org/10.3390/ijms24108776
work_keys_str_mv AT ruizvictorh innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation
AT encinasbasurtodavid innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation
AT sunbo innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation
AT eedarabasanthbabu innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation
AT roheunmiri innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation
AT alarconneftaliortega innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation
AT curiellewandrowskiclara innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation
AT bodeannm innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation
AT mansourheidim innovativerocuroniumbromidetopicalformulationfortargetedskindrugdeliverydesigncomprehensivecharacterizationinvitro2d3dhumancellcultureandpermeation